Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world

• Published in: International journal of clinical pharmacy Vol. 40; no. 3; pp. 608 - 616
• Main Authors: Uriarte-Pinto, Moisés, Navarro-Aznarez, Herminia, De La Llama-Celis, Natalia, Arazo-Garcés, Piedad, Martínez-Sapiña, Ana María, Abad-Sazatornil, María Reyes
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2018; Springer Nature B.V
• Subjects: Antiretroviral agents; Antiretroviral drugs; Antiviral agents; Antiviral drugs; Clinical trials; Fibrosis; Genotypes; Hepatitis; Hepatitis C; HIV; Human immunodeficiency virus; Internal Medicine; Liver; Medicine; Medicine & Public Health; Patients; Pharmacy; Research Article; Security; Slopes; Toxicity; HIV-HCV Coinfection; Drug-drug interactions; Sustained virologic response; Antiretroviral therapy; Direct-acting antivirals
• ISSN: 2210-7703; 2210-7711
• DOI: 10.1007/s11096-018-0621-0

Background HIV–HCV coinfection produces high morbi-mortality. Direct-acting antivirals (DAAs) have shown high efficacy, although special attention should be paid to the risk of drug interactions. However, due to the lack of representativeness of coinfected patients in clinical trials, it is important to know real-world results. Objective To evaluate DAA treatment effectiveness in coinfected patients. We also analyse safety profile of DAA treatment and drug interactions between HCV and HIV therapy. Setting Descriptive study carried in a tertiary hospital of Spain Method HIV–HCV coinfected patients treated with DAAs between November 2014 and June 2016 were included. Main outcome measure Efficacy was measured in terms of sustained virologic response at week 12 after the end of therapy. Adverse events that led to treatment discontinuation were registered to evaluate the safety profile, and also drug interactions between DAAs and antiretroviral treatment were evaluated. Results Main HCV genotypes were 1a (34.9%) and 4 (24.5%). 51.9% were HCV previously treated, 54.7% had grade 4 liver fibrosis. SVR12 was reported in 90.6%. HCV treatment was well tolerated and there were no discontinuations because of adverse events. 30.2% of HIV treatments had to be modified before DAA treatment was started due to interactions, HIV suppression was not compromised. Conclusion DAA treatment in coinfected patients seems to be highly effective and secure. Evaluation of drug interactions must be a priority in order to maximize effectiveness and avoid toxicity.